I agree with you but not only for XOMA. Why do any deal with any of the biotechs? It seems like it would be cheaper to just buy them up. Unless, and I believe this is the case, the deals are done on such favorable terms to the big pharmas that there is no need to clutter up ones company with an extra layer of management and staff that it is costly or messy to remove.
BTW, new patent re BPI and gram positive bacteria. It is a continuation of a previous patent and obviously the stock is doing so well that there is no need to try to make the market aware of this old information. <g>
United States Patent
5,783,561
Horwitz, et. al.
Jul. 21, 1998
Anti-gram-positive bacterial methods and materials
Inventors:
Horwitz; Arnold (Los Angeles, CA); Lambert, Jr.; Lewis H. (Fremont, CA); Little, II; Roger G.
(Benicia, CA).
Assignee:
XOMA Corporation (Berkeley, CA).
Appl. No.:
758,116
Filed:
Nov. 25, 1996 |
